- Home
- CMMB vs CLPS Comparison
CMMB vs CLPS Comparison
Compare CMMB & CLPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- CLPS
- Stock Information
- Founded
- CMMB 2004
- CLPS 2005
- Country
- CMMB Israel
- CLPS Hong Kong
- Employees
- CMMB N/A
- CLPS N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- CLPS Computer Software: Prepackaged Software
- Sector
- CMMB Health Care
- CLPS Technology
- Exchange
- CMMB Nasdaq
- CLPS Nasdaq
- Market Cap
- CMMB 23.0M
- CLPS 26.6M
- IPO Year
- CMMB N/A
- CLPS 2018
- Fundamental
- Price
- CMMB $1.21
- CLPS $1.02
- Analyst Decision
- CMMB Strong Buy
- CLPS
- Analyst Count
- CMMB 2
- CLPS 0
- Target Price
- CMMB $9.00
- CLPS N/A
- AVG Volume (30 Days)
- CMMB 89.3K
- CLPS 4.8K
- Earning Date
- CMMB 05-27-2025
- CLPS 03-05-2025
- Dividend Yield
- CMMB N/A
- CLPS 12.75%
- EPS Growth
- CMMB N/A
- CLPS N/A
- EPS
- CMMB N/A
- CLPS N/A
- Revenue
- CMMB N/A
- CLPS $153,816,045.00
- Revenue This Year
- CMMB N/A
- CLPS N/A
- Revenue Next Year
- CMMB N/A
- CLPS N/A
- P/E Ratio
- CMMB N/A
- CLPS N/A
- Revenue Growth
- CMMB N/A
- CLPS 5.81
- 52 Week Low
- CMMB $0.60
- CLPS $0.68
- 52 Week High
- CMMB $2.55
- CLPS $1.70
- Technical
- Relative Strength Index (RSI)
- CMMB 46.51
- CLPS 49.54
- Support Level
- CMMB $1.15
- CLPS $0.94
- Resistance Level
- CMMB $1.31
- CLPS $1.07
- Average True Range (ATR)
- CMMB 0.09
- CLPS 0.03
- MACD
- CMMB -0.00
- CLPS 0.01
- Stochastic Oscillator
- CMMB 22.58
- CLPS 66.60
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About CLPS CLPS Incorporation
CLPS Inc is a holding company. The company through its subsidiaries provides information technology consulting and solutions institutions in the banking, insurance, and financial sectors, both in China and globally. Its products are Risk Control Platform, Transaction Acquiring Platform, Debt Collection Platform, Virtual Bank Training Platform, Credit Card System, and other related products. The company generates its revenue from IT consulting services, Customized IT solution services, and others. Generating the majority of its revenue from the IT consulting service.